...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum beta 2-microglobulin levels
【24h】

A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum beta 2-microglobulin levels

机译：基于粘膜相关淋巴组织国际预后指数和血清β2-微球蛋白水平的外延边缘区淋巴瘤预后指标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The mucosa-associated lymphoid tissue (MALT) International Prognostic Index (IPI) was recently proposed as a prognostic index for patients with MALT lymphoma. We aimed to investigate the prognostic value of the serum beta 2-microglobulin level in the context of MALT-IPI, and we proposed a new prognostic index. Survival outcomes were analysed with regard to beta 2-microglobulin level, MALT-IPI, and the new prognostic index in MALT lymphoma patients (n = 571). The validity of the new prognostic index was assessed using an independent cohort (n = 216). Patients with high beta 2-microglobulin levels had significantly worse progression-free survival (PFS) and overall survival (OS) outcomes. A high beta 2-microglobulin level was independently associated with poor PFS and OS. beta 2-microglobulin levels further stratified patients in the MALT-IPI intermediate-risk group in terms of PFS and OS. A new prognostic index based on the MALT-IPI and the beta 2-microglobulin level, MALT-IPI-B, was proposed. The MALT-IPI-B was able to stratify patients into subgroups having distinct PFS and OS outcomes in both the training and validation cohorts. MALT-IPI-B enabled the identification of patients with poor survival outcomes who were classified into the intermediate-risk group by the MALT-IPI. In conclusion, this new beta 2-microglobulin-based prognostic index may have the specific advantage of identifying high-risk patients who may require systemic treatment.
机译：最近提出了粘膜相关淋巴组织（麦芽）国际预后指数（IPI）作为麦芽淋巴瘤患者的预后指数。我们旨在探讨麦芽-IPI背景下血清β2-微球蛋白水平的预后价值，并提出了新的预后指数。关于β2-微球蛋白水平，麦芽蛋白质和麦芽淋巴瘤患者的新预后指数分析生存结果（n = 571）。使用独立的队列评估新预后指数的有效性（n = 216）。高β2-微球蛋白水平的患者显着越差，无进展的存活率（PFS）和总存活（OS）结果。高β2-微球蛋白水平与差PFS和OS独立相关。 β2-微球蛋白水平在PFS和OS方面，麦芽-IPI中性风险组进一步分层患者。提出了一种基于Malt-IPI和β2-微球蛋白水平的新的预后指数，MALT-IPI-B。麦芽IPI-B能够将患者分成培训和验证队列中具有不同PFS和OS结果的亚组。 Malt-IPI-B使患有麦芽IPI分类为中级风险群体的患者的患者。总之，这种新的β2-微球蛋白的预后指数可能具有鉴定可能需要全身治疗的高风险患者的具体优势。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号